Common Heartburn Drug Studied As COVID-19 Treatment

The video discusses a study at Northwell Health hospitals in New York City, where patients are receiving higher doses of Famotidine, the active ingredient in Pepcid, to treat COVID-19. The study is based on an unpublished Chinese report suggesting potential benefits. Some patients are also receiving hydroxychloroquine, previously touted by President Trump as a 'Game Changer.' However, recent studies suggest hydroxychloroquine may be ineffective, leading to hesitancy in promoting trials to avoid a run on heartburn medication. Dr. Kevin Tracy emphasizes the need for clinical trials to determine Famotidine's efficacy.

How many patients are included in the New York study mentioned?

What did Doctor Kevin Tracy say about the availability and cost of Famotidine?